CompanyINONasdaqPlymouth Meeting, PA

Inovio Pharmaceuticals

Inovio develops DNA plasmid medicines delivered via its proprietary CELLECTRA device.

SEC EDGAR ClinicalTrials.gov ir.inovio.com

8-KAug 12Latest SEC filing, period to Aug 12

Sep 2Latest story

September 2026

Inovio's UCa-001 trial completes; results posted for INO-5401 combo in urothelial carcinoma

Sep 2Trial updateINO-5401 INO-9012

August 2026

Inovio's INO-3107 BLA review advances toward October 30 PDUFA date

Aug 12Quarterly updateInovio Pharmaceuticals

July 2026

Inovio prices $20 million public offering of stock and warrants

Jul 31FinancingInovio Pharmaceuticals

Inovio discloses preliminary cash of $36.7 million as of June 30, 2026

Jul 29Quarterly updateInovio Pharmaceuticals